Goldman Sachs Group Inc Cytokinetics Inc Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,273,983 shares of CYTK stock, worth $75.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,273,983
Previous 1,362,958
6.53%
Holding current value
$75.1 Million
Previous $54.8 Million
23.16%
% of portfolio
0.01%
Previous 0.01%
Shares
23 transactions
Others Institutions Holding CYTK
# of Institutions
375Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.04 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$865 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$707 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$462 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$376 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.55B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...